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Tobacco smoke and its metabolites are carcinogens that increase tissue oxidative stress and induce target tissue
inflammation. We hypothesized that genetic variation of inflammatory pathway genes plays a role in tobacco-related
carcinogenesis and is modified by tobacco smoking. We evaluated the association of 12 single nucleotide polymorphisms of 8
inflammation-related genes with tobacco-related cancers (lung, oropharynx, larynx, esophagus, stomach, liver, bladder, and
kidney) using 3 case-control studies from: Los Angeles (population-based; 611 lung and 553 upper aero-digestive tract cancer
cases and 1,040 controls), Taixing, China (population-based; 218 esophagus, 206 stomach, 204 liver cancer cases, and 415
Key words: IL10, TNF, single nucleotide polymorphisms, inflammation, tobacco-related cancer
Abbreviations aOR: adjusted odds ratio; aROR: adjusted ratio of odds ratios; BFDP: Bayesian false discovery probability; CI: confi-
dence interval; cOR: crude odds ratio; FPRP: false positive report probability; HWE: Hardy-Weinberg equilibrium; LA: Los Angeles;
MAF: minor allele frequency; MSKCC: Memorial Sloan-Kettering Cancer Center; NSCLC: non-small cell lung cancer; OR: odds ratio;
ROR: ratio of odds ratios; SCC: squamous cell carcinoma; SNP: single nucleotide polymorphism; sOR: summary odds ratio; UADT:
upper aero-digestive tract
Additional Supporting Information may be found in the online version of this article.
Grant sponsor: NIH National Institute of Environmental Health Sciences (National Cancer Institute, Department of Health and Human
Services); Grant numbers: ES06718, ES01167, DA11386, CA90833, CA77954, CA09142, CA96134, CA128099, GM53275; Grant sponsors:
Alper Research Center for Environmental Genomics, The Seymour Family Gift for Innovative Investigator-Initiated Research in Bladder
Cancer (UCLA Jonsson Comprehensive Cancer Center), UCLA Center for Occupational and Environmental Health
DOI: 10.1002/ijc.25214
History: Received 16 Nov 2009; Accepted 18 Jan 2010; Online 28 Jan 2010
Correspondence to: Zuo-Feng Zhang, Department of Epidemiology, School of Public Health, University of California, Los Angeles, 71-225









Int. J. Cancer: 127, 2169–2182 (2010) VC 2010 UICC
International Journal of Cancer
IJC
controls), and Memorial Sloan-Kettering Cancer Center (hospital-based; 227 bladder cancer cases and 211 controls). After
adjusting for age, education, ethnicity, gender, and tobacco smoking, IL10 rs1800871 was inversely associated with
oropharyngeal cancer (CT1TT vs. CC adjusted odds ratio [aOR]: 0.69, 95% confidence interval [CI]: 0.50–0.95), and was
positively associated with lung cancer among never smokers (TT vs. CT1CC aOR: 2.5, 95% CI: 1.3–5.1) and inversely with
oropharyngeal cancer among ever smokers (CT1TT vs. CC aOR: 0.63, 95% CI: 0.41–0.95). Among all pooled never smokers
(588 cases and 816 controls), TNF rs1799964 was inversely associated with smoking-related cancer (CC vs. CT1TT aOR: 0.36,
95% CI: 0.17–0.77). Bayesian correction for multiple comparisons suggests that chance is unlikely to explain our findings
(although epigenetic mechanisms may be in effect), which support our hypotheses, suggesting that IL10 rs1800871 is a
susceptibility marker for oropharyngeal and lung cancers, and that TNF rs1799964 is associated with smoking-related cancers
among never smokers.
Tobacco smoking is a major risk factor for malignancies of
the lung, upper aero-digestive tract (UADT), stomach, pan-
creas, liver, kidney, urinary tract, uterine cervix, and bone
marrow. Epithelial cells in many of these organs are repeat-
edly exposed to components and metabolites of tobacco
smoke, which are carcinogenic and potent inducers of
inflammation. The high concentration of free radicals con-
tained in and generated by tobacco smoke can lead to cancer
through oxidative DNA damage mediated by inflammation-
associated production of reactive oxygen species.
Chronic inflammation, characterized in part by altered
cytokine levels, is believed to play a role in tumor initiation
and promotion. Inflammatory conditions such as ulcerative
colitis and inflammatory bowel disease have well-established
associations with colorectal cancer,1 and lung cancer has
been connected to inflammatory diseases such as tuberculosis
and pneumonia.2,3 Additionally, cancers of the stomach, liver,
and esophagus have been attributed to chronic inflammation
as a result of persistent infection.4 An individual’s cancer risk
may be affected by genetic variations in essential cell regula-
tory pathways5,6 and inflammatory responses,7,8 and tobacco
smoking may modify these effects,9,10 suggesting that genetic
variation may be important susceptibility markers for
tobacco-related cancers.
In the current study, we use a pathway-based approach
using data from 3 case-control studies (Los Angeles [LA]
County, Taixing, China, and Memorial Sloan-Kettering Can-
cer Center [MSKCC]) to test the hypotheses that single nu-
cleotide polymorphisms (SNPs) in inflammation-related
genes are associated with smoking-related cancers of the
lung, oropharynx, larynx, esophagus, stomach, liver, bladder,
and kidney, and that their effects are modified by tobacco
smoking.
Material and Methods
Study design and participants
Detailed descriptions of the 3 case-control studies reported in
this manuscript have been published for the LA,11 Taixing,12
and MSKCC13 and studies, which are briefly described later.
All study participants provided written consent, and study
protocols were approved by appropriate review boards. Sub-
jects not meeting study-specific inclusion criteria were
excluded from enrollment.
The LA study was population-based, consisting of histo-
logically confirmed incident lung (n ¼ 611) and UADT (n ¼
553) cancer cases obtained from the LA County cancer regis-
try administered through the Cancer Surveillance Program at
the University of Southern California; 1,040 controls without
a history of lung or UADT cancer were matched on gender,
age, and residential neighborhood, using an algorithm to
identify eligible controls from a census of each case’s neigh-
borhood. To be eligible, subjects had to be (i) 18–65 years of
age during 1999–2004, (ii) a resident of LA County at time
of diagnosis (cases) or recruitment (controls), and (iii) able
to speak English or Spanish, or have a translator available at
home. Recruitment rates among eligible cases were 39 and
46% for lung and UADT cases, respectively, and 79% for
controls. Buccal cell samples were obtained at the end of
interviews for DNA analysis.
The Taixing study was also population-based and con-
ducted in 2000. Newly diagnosed and pathologically or clini-
cally confirmed cases of stomach (n ¼ 206), liver (n ¼ 204),
and esophageal (n ¼ 218) cancers were obtained from the
Taixing Tumor Registry operated through the Taixing Center
for Disease Control and Prevention. A common group of
healthy controls from the general population registry (n ¼
415) was frequency matched by age, gender, and village. Eli-
gibility criteria required that all subjects were (i) at least 20
years old, (ii) in stable medical condition, and (iii) living in
Taixing for at least 10 years. Recruitment rates were 67, 65,
and 57% for eligible esophagus, stomach, and liver cancer
cases, respectively, and 89% for controls. Blood samples were
collected at the end of interviews for DNA analysis.
The MSKCC study, conducted during 1993–1997, was
hospital-based and consisted of 227 pathologically confirmed
bladder cancer cases sampled from the MSKCC who had
recently been diagnosed or undergone bladder surgery. Two-
hundred and eleven controls who had resided in the United
States for at least a year were recruited from the MSKCC
blood bank or from MSKCC patients who did not have can-
cer diagnoses and were in stable medical condition. Ninety-
five percent of cases and 92% of controls agreed to partici-
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Standardized questionnaires appropriate for each of the 3
studies were administered in person by trained staff. Data
collected across all 3 studies included demographic informa-
tion; detailed behavioral factors such as diet, alcohol use, and
exposure to tobacco smoke; other environmental and occupa-
tional exposures; personal and family medical histories; and
other exposures considered known or possible risk factors for
cancers specific to each study. Between-study variation
among the common demographic variables was greatest for
race/ethnicity, which was most heterogeneous in the LA
study (59.3% White, 17.0% Hispanic, 11.9% African–Ameri-
can, 8.7% Asian–American, and 3.0% other) and least in the
Taixing study (100% Chinese); less than 5% of MSKCC study
participants were non-White.
SNP selection and analysis
We focused on functional and potentially functional SNPs
(such as amino acid-changing polymorphisms) and SNPs
located in regions regulating gene transcription (such as pro-
moter areas). We decided a priori to exclude SNPs from
analysis that did not meet the following criteria among the
study-specific control groups: (i) minor allele frequency
(MAF) 5%, (ii) Hardy-Weinberg equilibrium (HWE) p-
value > Bonferroni-adjusted p-value, and (iii) genotyping call
rate 80% for SNPlex and 95% for TaqMan.
The majority of SNPs that violated HWE in our initial
pool of SNPs were excluded from analysis due to low geno-
typing rates or minor allele frequencies. After using a Bonfer-
roni-adjusted cut-point among the study-specific control
groups to assess deviations from HWE, 1 SNP was excluded
from the LA study (TNF rs1799724 HWE p value < 0.0001),
another SNP was dropped from the Taixing study (IL13
rs20541 HWE p value < 0.0001), and 1 more from the
MSKCC study (IL13 rs20541 HWE p value ¼ 0.00018). The
final pool of SNPs included in our study had allele frequen-
cies that were in the expected range of normal variation, and
none had HWE p < 0.05 among the study-specific control
groups. Six SNPs met these criteria across all 3 studies (IL10
rs1800871, TNF rs1799964, TNF rs1800629, LTA rs909253,
IFNGR1 rs11914, and IFNG rs2069705), whereas another 6
met inclusion criteria for at least 1 of the studies (IL10
rs1800872, IL10 rs1800896, IL1A rs17561, IL1B rs1143627,
IL1B rs16944, and IL6 rs1800796). These 12 SNPs and details
of their inclusion criteria are reported in Supporting Informa-
tion Table S1. Because population substructure can affect a
SNP’s distribution, we also examined HWE by ethnicity in
the LA study. At an alpha level of 0.05, deviation from HWE
was suggested for several SNPs (IL1B rs1143627 among His-
panics, IL10 rs1800871 in Asian-Americans, and LTA
rs909253 for African-Americans), but none exceeded the
Bonferroni-adjusted cut-point of 0.05/12 ¼ 0.0042. In instan-
ces where 2 or more SNPs are in strong linkage disequili-
brium (i.e., r2  0.9), the SNP with the more reliable signal
is presented. Although 3 SNPs in the IL10 promoter region
were within 0.5 kb of each other (rs1800896, rs1800871, and
rs1800872), haplotype analysis was not conducted as
rs1800896 was not genotyped in the LA and MSKCC studies,
and because initial analysis suggested a block size of only 2
SNPs in the Taixing study.
Laboratory analysis
DNA was isolated using a modified phenol–chloroform
method. SNPs were genotyped using the SNPlex assay
(Applied Biosystems [ABI], Foster City, CA); 2 were also
genotyped with ABI’s TaqMan assay (IL10 rs1800871 and
IFNGR1 rs11914). Briefly, DNA aliquots from cases and con-
trols were randomized onto PCR plates with the appropriate
reaction mix. For SNPlex reactions, allele-specific oligonu-
cleotide probes were hybridized to target genomic sequences.
The hybridization products were purified of excess probe,
amplified by PCR, and captured in streptavidin-coated micro-
titer plates. Fluorescently labeled ZipChute probes were then
hybridized to the streptavidin-bound amplicons and detected
by capillary electrophoresis. In the TaqMan assay, fluores-
cently labeled sequence-specific primers were used in PCR
reactions in a total volume of 5 ll with the following modi-
fied protocol: denaturation at 92C for 10 min followed by
60 cycles at 92C for 15 sec and extension at 62C for
80 sec. Genotype detection for SNPlex and TaqMan assays
was performed using an ABI 3730 DNA Analyzer with ABI
Genemapper 4.0 software and an ABI 7900 machine with
SDS 2.3 software, respectively. Call rates were >85% for
SNPlex and >97% for TaqMan. Reproducibility was 0.978
for the SNPlex assay (based on regenotyping a 3% random
sample), and 0.997 for the TaqMan assay (using a 5% ran-
dom sample). Concordance for SNPs genotyped on both
platforms was 0.943 for IL10 rs1800871 and 0.996 for
IFNGR1 rs11914.
Statistical analysis
Fisher’s exact test was used to assess deviation from HWE,
and all data were analyzed with SAS version 9.1.3. The odds
ratio (OR) and 95% confidence interval (CI) for each SNP-
cancer association of each study and within smoking strata
were estimated using unconditional logistic regression. To
test the hypothesis that an increasing number of risk alleles
is associated with cancer (i.e., monotonic-response model),
we tested for linear trend of the odds ratio by treating the
number of risk alleles as a continuous variable in logistic
regression models, designating the homozygous ancestral ge-
notype the as the reference group based on SNP-specific in-
formation at the National Center for Biotechnology Informa-
tion’s dbSNP database.14 We used these cancer site-specific
genotype-cancer associations for each SNP to determine the
appropriateness of selecting an inheritance model (e.g., domi-
nant, recessive). Covariates in the LA study included race/
ethnicity (non-Hispanic White, Hispanic, African-American,
Asian-American, and other), pack-years of tobacco smoking
(continuous), drink-years of alcohol consumption for UADT
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To minimize confounding, age was divided into fine catego-
ries (29–34, 35–36, 37–38, 39–40, 41–42, 43–44, 45–46, 47–
48, 49–50, 51–52, 53–54, 55–56, 57–58, and 59–62), and con-
trols who were more than 3 years older than the oldest case
or more than 3 years younger than the youngest case were
excluded. This resulted in the exclusion of 11 controls from
lung cancer analyses; no controls were excluded from UADT
analyses. Analyses in the Taixing study were adjusted for
gender, alcohol drinking (4-level ordinal), education (4-level
ordinal), age (continuous), pack-years (continuous), hepatitis
B surface antigen for liver cancer, and Helicobacter pylori
infection status for stomach cancer. Regression models in the
MSKCC study included race (White vs. non-White), gender,
smoking status (ever vs. never), age (continuous), and years
of education (continuous). Stratified analyses by smoking sta-
tus (ever and never smokers) were limited to instances for
which there were at least 75 cases to ensure adequate preci-
sion, and pack-years of smoking was included in regression
models to address residual confounding among ever smokers.
We tested the effects of the SNPs and tobacco smoking for
departure from multiplicativity by fitting a model with smok-
ing (ever/never), genotype, and their product term, and cal-
culating the ratio of odds ratios (ROR) by taking the natural
antilog of the estimated coefficient of the product term.
Potential confounders, including ethnicity, age, gender, and
pack-years of smoking were included in logistic regression
models, and individuals with the nonrisk genotype who had
never smoked were designated as the reference group.
For SNPs genotyped across all 3 studies that had point
estimates consistent in direction and magnitude over all can-
cer sites, we investigated whether those SNPs were associated
with smoking-related cancer by pooling all cases and controls
across all 3 studies and the different tumor sites. We adjusted
for study location, gender, race/ethnicity, age, and tobacco
smoking (ever vs. never). Because race/ethnicity is highly cor-
related with study location, we tested for the presence of
multicollinearity by assessing the variance inflation factor and
by testing for heterogeneity between models with and without
terms for ethnicity. Neither method suggested that multicolli-
nearity was an important factor, so categories for race/ethnic-
ity and study location were combined into 1 variable and
included as a new covariate in adjusted logistic regression
analyses for pooled cancer sites.
Given the number of comparisons made in this study, we
addressed the possibility of chance findings using 2 Bayesian
approaches. The false positive report probability (FPRP) facil-
itates identifying noteworthy observations when the probabil-
ity of a false positive is below an investigator-predetermined
threshold.15 The Bayesian false discovery probability (BFDP)
is a progression of FPRP and considers the ratio of the cost
of missing a true association to the cost of a false discovery.16
In both methods, an observation from our study was viewed
in light of prior knowledge (i.e., prior probability) to assess
the posterior probability that the association is not null. The
value of the prior probability is subjective and guided by epi-
demiologic data and existing knowledge of the gene and
related SNPs. We considered prior probabilities ranging from
0.10 to 0.01, a main effect OR of 1.5 (or 0.67), a smoking-
stratified OR of 2.5 (or 0.40), and a FPRP cut-point of 0.4
and a BFDP threshold of 0.8 to determine noteworthy
findings.
Results
Characteristics of our study population of 2,049 smoking-
related cancer cases and 1,666 controls are presented in Table 1.
When compared with the LA and MSKCC studies, the ma-
jority of Taixing participants had completed less than 12
years of education and was less likely to have reported ever
drinking alcohol. Controls were noticeably younger than
cases in the MSKCC study. The estimated effects of the 12
SNPs stratified by cancer site are reported in Supporting
Information Tables S2 and S3; selected results are summar-
ized in Figure 1a. Oropharyngeal cancer was inversely asso-
ciated with IL10 rs1800871 among CT heterozygotes
(adjusted OR [aOR]: 0.67, 95% CI: 0.48–0.94) and possibly
among TT homozygotes (aOR: 0.78, 95% CI: 0.44–1.4),
suggesting a dominant inheritance model (aOR: 0.69, 95%
CI: 0.50–0.95). An inverse association was also observed
between IFNG rs2069705 and oropharyngeal cancer (CT
and TT versus CC aOR: 0.72, 95% CI: 0.52–1.0) (Support-
ing Information Table S2). When compared with IL1B
rs16944 GG homozygotes, the A allele was more common
among lung cancer cases (aOR: 1.3, 95% CI: 1.0–1.8). This
association, which was not modified by smoking status,
appeared to be consistent across ethnicity.
Because tobacco smoking is a strong risk factor for our
outcomes, we re-examined the SNP-cancer associations, strat-
ifying by ever/never smoking status. These results are
reported in Supporting Information Table S4 and summar-
ized in Figure 1a. Lung cancer was associated with IL10
rs1800871 among never smokers (TT versus CC or CT aOR:
2.5, 95% CI: 1.3–5.1) but not among ever smokers, though
there was some heterogeneity across ethnicity. Although the
point estimate for Whites was less than 1.0, estimates were
greater than 1.0 for the other ethnicities, though they tended
to be imprecise. Oropharyngeal cancer was inversely associ-
ated with IL10 rs1800871 among ever smokers (CT or TT
versus CC aOR: 0.63, 95% CI: 0.41–0.95) and positively asso-
ciated with IFNG rs2069705 among never smokers (CC ver-
sus CT or TT aOR: 1.9, 95% CI: 1.0–3.5). Esophageal cancer
in the Taixing study was less common among ever smokers
who had at least 1 variant G allele for IFNGR1 rs11914
(aOR: 0.38, 95% CI: 0.18–0.80). Risk estimates for SNP-can-
cer associations after restricting to current smokers were in
the same direction as smoking stratified results but greater in
magnitude (i.e., further from the null) and less precise.
Of the 6 SNPs that were genotyped across all 3 studies,
the most consistent SNP-cancer estimates were observed for
TNF rs1799964 among never smokers. Smoking-related can-
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homozygous for the variant TNF rs1799964 C allele com-
pared with never smokers with at least 1 T allele (aOR: 0.36,
95% CI: 0.17–0.77). This inverse association was not observed
among ever smokers (Fig. 1b and Supporting Information
Table S5). When stratified by ethnicity, the relative rarity of
cancers among never smokers compared with ever smokers
tended to persist, although smoking-stratified estimates for
some ethnicities were imprecise.
The estimated effects of genotype-smoking-status combi-
nations for selected SNPs are shown in Table 2. In site-strati-
fied analysis, we observed that the estimated joint effect of re-
cessive IL10 rs1800871 genotype and tobacco smoking was
less than what would be expected under the null hypothesis
of multiplicativity of effects among lung cancer cases and
controls (aROR: 0.31, 95% CI: 0.14–0.69), which persisted
across ethnicity, although adjusting for pack-years attenuated
the estimate. There was also an indication of departure from
multiplicative effects for IFNGR1 rs11914 and esophageal
cancer in the Taixing study (aROR: 0.37, 95% CI: 0.13–1.0).
In our pooled analysis, there was evidence of greater than
multiplicative interaction among individuals recessive for
TNF rs1799964 (aROR: 3.4, 95% CI: 1.4–8.6), which was
fairly consistent across ethnicity with the exception of Afri-
can-Americans, whose unstable estimates were a reflection of
that group having the least number of individuals homozy-
gous for the rare genotype among controls.
Given the many comparisons in our study, we considered
the probability of chance finding (Supporting Information
Table S6). Assuming a prior probability of 0.10 and a FPRP
cut-point of 0.4, the associations between lung cancer and
IL1B rs16944 and between oropharyngeal cancer and poly-
morphisms of IL10 rs1800871 and IFNG rs2069705 appear to
be noteworthy. Under the same prior, and assuming that
false nondiscovery is 4 times as costly as false discovery (i.e.,
a BFDP threshold of 0.8), the association between oropharyn-
geal cancer and IL10 rs1800871 may be important. Consider-
ing associations that are below both FPRP and BFDP thresh-
olds, IL10 rs1800871 appears to be an important marker for
oropharyngeal cancer risk. IL10 rs1800871 may also be asso-
ciated with lung cancer among never smokers and with oro-
pharyngeal cancer among ever smokers. Chance does not
seem to be a likely explanation in our study population. The
TNF rs1799964 SNP, which only appeared to be associated
with stomach cancer in site-specific analyses, also seems to
be associated with smoking-related cancers among never
smokers, even at a 5% prior probability. Additional associa-
tions adjusted for multiple comparisons may be noteworthy
for several other smoking-stratified associations at a prior
probability of 0.10 but none passed FPRP and BFDP criteria
using more conservative priors.
Discussion
Among never smokers in our overall study population of
2,049 cases and 1,666 controls, we found that TNF rs1799964
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Figure 1. (a) Selected single nucleotide polymorphism-cancer associations (black boxes) stratified by cancer site and smoking status
(white and hatched boxes represent never and ever smokers, respectively). Odds ratios (OR) and 95% confidence intervals (CI) adjusted
for age, gender, education, tobacco smoking, ethnicity, and alcohol use (oropharynx and esophagus). (b) TNF rs1799964-cancer
associations (black boxes) among pooled cancer cases and controls stratified by ethnicity and smoking status (white and hatched boxes
represent never and ever smokers, respectively). Odds ratios (OR) and 95% confidence intervals (CI) adjusted for study location, age,
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Table 2. Modification of selected SNP-specific odds ratios for tobacco-related cancers pooled and stratified by ethnicity,
smoking status, and cancer site




All cancer sites pooled No TT þ CT 434 633 1.0 1.0
No CC 10 35 0.42 0.20–0.85 0.41 0.19–0.85 0.22 0.37 0.76
Yes TT þ CT 1,044 650 2.3 2.0–2.7 2.4 2.0–2.8 <0.01 <0.01 <0.01
Yes CC 45 20 3.3 1.9–5.6 3.3 1.9–5.8 <0.01 <0.01 0.02
ROR 3.4 1.4–8.2 3.4 1.4–8.6 0.25 0.41 0.78
White No TT þ CT 111 329 1.0 1.0
No CC 1 12 0.25 0.03–1.9 0.26 0.03–2.1
Yes TT þ CT 528 314 5.0 3.9–6.4 3.6 2.8–4.8 <0.01 <0.01 <0.01
Yes CC 25 9 8.2 3.73–18 6.7 2.9–15 0.01 0.01 0.07
ROR 6.7 0.74–60 7.1 0.76–66
Hispanic No TT þ CT 43 75 1.0 1.0
No CC 0 3
Yes TT þ CT 77 102 1.3 0.82–2.1 1.3 0.80–2.2
Yes CC 6 1 10 1.2–90 11 1.3–97 0.75 0.87 0.87
ROR
African-American No TT þ CT 19 29 1.0 1.0
No CC 1 1 1.5 0.11–32 2.7 0.15–49
Yes TT þ CT 103 43 3.7 1.9–7.2 3.5 1.8–7.1 0.02 0.05 0.20
Yes CC 1 1 1.5 0.09–26 1.8 0.10–31
ROR 0.28 0.01–15 0.18 0.004–11
Asian-American No TT þ CT 36 26 1.0 1.0
No CC 1 3 0.23 0.02–2.4 0.24 0.02–2.5
Yes TT þ CT 38 21 1.3 0.60–2.6 1.3 0.63–2.7
Yes CC 3 1 2.1 0.20–22 2.2 0.21–22
ROR 6.8 0.25–181 10.0 0.31–332
Han Chinese No TT þ CT 221 164 1.0 1.0
No CC 7 14 0.37 0.15–0.94 0.38 0.14–0.98 0.47 0.65 0.91
Yes TT þ CT 283 151 1.4 1.1–1.8 1.5 1.1–2.2 0.18 0.31 0.70
Yes CC 8 8 0.74 0.27–2.0 0.78 0.27–2.2
ROR 1.4 0.37–5.6 1.4 0.33–5.4
IL10 rs1800871
Lung No CC þ CT 63 387 1.0 1.0
No TT 28 33 5.2 3.0–9.2 3.1 1.6–5.9 0.02 0.04 0.19
Yes CC þ CT 387 424 5.6 4.2–7.6 1.2 0.82–1.8
Yes TT 47 61 4.7 3.0–7.5 1.2 0.68–2.1
ROR 0.16 0.08–0.33 0.31 0.14–0.69 0.12 0.23 0.60
White No CC þ CT 24 263 1.0 1.0
No TT 1 10 1.1 0.13–8.9 1.0 0.12–8.3
Yes CC þ CT 270 266 11 7.1–17 1.8 1.0–3.2 0.29 0.46 0.82
Yes TT 15 22 7.5 3.4–16 1.2 0.45–3.2
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specific analysis suggests that oropharyngeal cancer is inver-
sely associated with IL10 rs1800871 and IFNG rs2069705.
Smoking-stratified analyses suggest that some SNP-cancer
associations become more apparent within strata of smoking
status and that some associations may be site-specific. TNF
rs1799964, for example, seems to be an important SNP
among never smokers for smoking-related cancer as a whole,
while the IL10 rs1800871 association with lung cancer was
observed only among never smokers (aOR: 2.5, 95% CI: 1.3–
5.1 vs. aOR: 1.0, 95% CI: 0.61–1.7 for ever smokers). After
adjustment for multiple comparisons, the associations between
TNF rs1799964 and any smoking-related cancer among never
smokers and between IL10 rs1800871 and cancers of the oro-
pharynx and lung do not appear to be due to chance.
Whether IL10 polymorphisms affect lung cancer risk
remains to be determined but some reports suggest an
Table 2. Modification of selected SNP-specific odds ratios for tobacco-related cancers pooled and stratified by ethnicity,
smoking status, and cancer site (Continued).
SNP and cancer site Ever smoker Genotype Case Control cOR 95% CI aOR 95% CI
FPRP prior probability
0.10 0.05 0.01
Hispanic No CC þ CT 19 71 1.0 1.0
No TT 9 10 3.4 1.2–9.5 3.8 1.2–12 0.43 0.61 0.89
Yes CC þ CT 30 87 1.3 0.67–2.5 0.72 0.31–1.7
Yes TT 5 20 0.93 0.31–2.8 0.70 0.21–2.3
ROR 0.21 0.05–0.93 0.25 0.05–1.2
African-American No CC þ CT 8 28 1.0 1.0
No TT 0 1
Yes CC þ CT 58 42 4.8 2.0–12 1.1 0.33–3.8
Yes TT 17 6 9.9 2.9–34 4.7 1.1–21 0.65 0.80 0.95
ROR
Asian-American No CC þ CT 9 16 1.0 1.0
No TT 18 11 2.9 0.96–8.8 3.7 1.1–12 0.52 0.70 0.92
Yes CC þ CT 18 10 3.2 1.0–10 0.76 0.15–3.9
Yes TT 10 12 1.5 0.46–4.8 0.48 0.10–2.4
ROR 0.17 0.03–0.84 0.18 0.03–1.1
IFNG rs2069705
Oropharynx No TT þ CT 60 339 1.0 1.0
No CC 21 67 1.8 1.0–3.1 1.9 1.0–3.4 0.30 0.47 0.82
Yes TT þ CT 115 360 1.8 1.3–2.6 0.82 0.52–1.3
Yes CC 16 90 1.0 0.55–1.8 0.48 0.24–0.98 0.36 0.55 0.86
ROR 0.31 0.14–0.70 0.31 0.13–0.73 0.19 0.33 0.72
White No TT þ CT 44 233 1.0 1.0
No CC 8 21 2.0 0.84–4.8 2.0 0.83–5.0
Yes TT þ CT 79 239 1.8 1.2–2.6 0.90 0.51–1.6
Yes CC 3 25 0.64 0.18–2.2 0.39 0.11–1.4
ROR 0.18 0.04–0.81 0.21 0.05–1.0 0.68 0.82 0.96
IFNGR1 rs11914
Esophagus (Taixing) No TT 67 161 1.0 1.0
No GT þ GG 17 36 1.1 0.60–2.2 1.1 0.55–2.2
Yes TT 96 141 1.6 1.1–2.4 2.0 0.97–4.0
Yes GT þ GG 12 42 0.69 0.34–1.4 0.74 0.29–1.9
ROR 0.40 0.15–1.0 0.37 0.13–1.0 0.51 0.68 0.92
Abbreviations: aOR: odds ratio (OR) adjusted for study location/ethnicity (pooled analysis only), ethnicity (lung analysis only), age, gender,
education, tobacco smoking, and alcohol use (oropharynx and esophagus analyses only); CI: confidence interval; cOR: crude OR; FPRP: false
positive report probability. FPRP values are the posterior probabilities of reporting a false positive result, given the statistical power to detect a
smoking-stratified aOR or ROR of at least 2.5. Values of FPRP less than 0.4 are bold-faced, indicating noteworthy observations; ROR: ratio of odds
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association, although differences in models of inheritance and
risk estimates suggest some heterogeneity. A population-
based case-cohort study estimated a 60% increase in lung
cancer risk for individuals with at least 1 copy of the IL10
rs1800872 variant A allele (which is in high linkage disequili-
brium with rs1800871), and a slightly weaker association
among current smokers.17 A positive association between
non-small cell lung cancer (NSCLC) and IL10 rs1800871 was
estimated by Van Dyke et al. in a population-based case-con-
trol study among Caucasian women (aOR: 1.39, 95% CI:
0.96–2.02), and the magnitude of the association was still ele-
vated, though less precisely, among a smaller number of Afri-
can-American women (aOR: 1.32, 95% CI: 0.60–2.88).18 IL10
rs1800871 was recessively associated with NSCLC in a Chi-
nese population (OR: 1.37, 95% CI: 1.10–2.09) but it is not
clear if the estimate was adjusted for tobacco smoking, age,
sex, and gender, although those characteristics seemed simi-
larly distributed between cases and controls.19 Weaker associ-
ations between rs1800871 and lung cancer have also been
reported in a Chinese population homozygous for the rare al-
lele (aOR: 1.38, 95% CI: 0.57–3.38)20 and among non-His-
panic Caucasians with at least 1 variant T allele (aOR: 1.43,
95% CI: 0.78–2.63).21 Despite differences in interpreting the
association between IL10 rs1800871 and lung cancer, point
estimates from published studies (i.e., OR  1.4) are compa-
rable with our own estimate (aOR: 1.5, 95% CI: 0.96–2.2),
and the consistency between these estimates (p heterogeneity
> 0.99) further suggests that IL10 rs1800871 might be associ-
ated with elevated lung cancer risk, but the magnitude is not
large.
IL-10 expression in oropharyngeal squamous cell carci-
noma (SCC) has been inversely associated with survival22
and tumor grade and stage.23 However, these studies do not
rule out the possibility of association through altered cytokine
expression as a result of somatic mutations within the tumor.
Several studies of germline mutations suggest that IL10 poly-
morphisms, which are associated with periodontitis,24,25 may
also be associated with tongue cancer26 and oral neoplasms.27
IL10 rs1800896, which is not in high linkage disequilibrium
with rs1800871 (r2 ¼ 0.30), was associated with oral SCC in
a hospital-based case-control study (aOR: 2.65, 95% CI: 1.28–
5.46).28 Another study from Sichuan, China reported that
compared with the rs1800871 TT genotype, the CC genotype
(which is more common in Asian populations) was associ-
ated with oral cancer (OR: 1.45, 95% CI: 0.88–2.39).29 Recal-
culating the estimate with the CC genotype as the referent
group yields a measure of association (OR: 0.69, 95% CI:
0.42–1.14) which is nearly identical to the effect estimated in
our study (aOR: 0.69, 95% CI: 0.50–0.95).
Our results suggest that IL1B rs16944 may predict lung
cancer, consistent with published reports,30–32 but our associ-
ation did not hold after correction for multiple comparisons.
Based on a large, multicenter case-control study, IL1B
rs1143627 (linkage disequilibrium with rs16944: r2 ¼ 0.94)
was not associated with lung cancer, suggesting that our find-
ing for rs16944 may be due to chance.33 It is possible,
though, that the association of lung cancer with IL1B poly-
morphisms could involve a pathway that is not primarily
mediated by rs1143627.34,35
The involvement of TNF polymorphisms in cancer has
been reported for several malignancies, including lympho-
mas6,36,37 and lung cancer, though more null results have
been reported for lung cancer18,21,32,38 than non-null associa-
tions.39 The most consistent associations seem to come from
gastric cancer studies. A meta-analysis of TNF polymor-
phisms reported positive associations for rs1800629 (sum-
mary OR [sOR]: 1.49, 95% CI: 1.11–1.99) and rs1799724
(sOR: 1.57, 95% CI: 0.91–2.70).5 We observed a similar asso-
ciation for rs1800629 in our gastric cancer sample (aOR: 1.3,
95% CI: 0.74–2.4). The apparent lack of published associa-
tions for rs1799964 could be because it may be most noticea-
ble among nonsmokers, for whom the strong effect of
tobacco-smoking is not as important a risk factor.
The difference in effects estimated between never smokers
and ever smokers in our study suggests that smoking can
modify the rate ratios between some inflammation-related
SNPs and smoking related-cancers. In our pooled analysis,
for example, smoking-related cancers were less common
among never smokers with the TNF rs1799964 CC genotype,
and the variant C allele did not appear protective among
ever smokers (Table 2). Less than multiplicative smoking-
SNP interactions were also suggested between lung cancer
and IL10 rs1800871, oropharyngeal cancer and IFNG
rs2069705, and esophageal cancer and IFNGR1 rs11914.
The mechanisms underlying these observations are
unknown. Genetic polymorphisms in the numerous pathways
involved in carcinogenesis affect cancer risk, and tobacco
smoking may modify these effects.9,10,40,41 The epithelial cells
from many of the organs in our study are repeatedly exposed to
components of tobacco smoke or their metabolic byproducts,
which are carcinogenic,42 known to cause vasoconstriction,43
inhibit cell proliferation and angiogenesis,44,45 and are potent
inducers of inflammation.46,47 The high levels of free radicals
contained in48 and generated by tobacco smoke can lead to can-
cer through oxidative DNA damage mediated by inflamma-
tion-associated production of reactive oxygen species.49
Promoter polymorphisms of TNF are fairly numerous and
in linkage disequilibrium with each other and with nearby
genes,50 which may have cooperative effects,51 potentially
complicating the interpretation of single-SNP associations.
One of the most commonly studied TNF SNPs is the
rs1800629 G-308A polymorphism.52 The variant rs1799964 C
allele, which is not in linkage disequilibrium with the G-
308A polymorphism (r2 ¼ 0.07), appears to be associated
with increased TNF expression.53 TNF is an inflammatory
cytokine and its expression by peripheral blood mononuclear
cells has been demonstrated to increase following exposure to
tobacco smoke.54 Interestingly, TNF was expressed at higher
levels in cells from nonsmokers than smokers at all time-
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observation that smoking-related cancers were less common
among never smokers with the putative high expression TNF
rs1799964 CC genotype. Haplotype studies of the gene
encoding the anti-inflammatory cytokine IL-10 suggest that
the GCC haplotype (i.e., rs1800896 G, rs1800871 C, and
rs1800872 C) is associated with high IL-10 production.55,56
Although haplotype data were unavailable in the LA study,
the rs1800871 variant T allele associated with low production
appeared to be an important SNP for lung cancer among
never smokers, whereas the variant did not seem to increase
risk among ever smokers.
The Van Dyke study of NSCLC among women18 reported
associations for 6 SNPs that were also genotyped in our study
(IL1B rs1143627 and rs16944; TNF rs1799964 and rs1800629;
LTA rs909253; and IL10 rs1800871). The estimated magni-
tude and direction of association for these SNPs were similar
to our own estimates, both overall and among women,
although comparability of our TNF results was affected by
the small number of women with the variant C allele, result-
ing in unstable estimates. Although the majority of our SNPs
do not result in amino acid substitutions, cancers of the oro-
pharynx and lung appear to be associated with IL10
rs1800871. The SNPs may influence cancer in part through
modifying transcription and/or translation. Synonymous
SNPs have been demonstrated to alter protein structure by
affecting RNA splicing57 and the stability58,59 and translation
rate60 of mRNA. However, further work assessing how these
SNPs may affect transcription, translation, and protein con-
formation would help shed light on these hypothesized
mechanisms.
Our study design and analytic strategy had a number of
strengths and weaknesses. The associations in our study are
subject to confounding and biases related to information
ascertainment and subject selection. We included ethnicity as
a covariate in regression models to address admixture but the
effects of population stratification may still residually con-
found our estimates, particularly for SNPs with allele fre-
quencies that differ greatly between ethnicities, such as IL10
rs1800871 and IFNG rs2069705. The association we observed
between lung cancer and IL10 rs1800871, for example, might
be partially due to uncontrolled differences in ethnicity.
However, the ethnic diversity of the LA study facilitated ex-
amination of ethnicity-specific ratios of odds ratios, which
were consistent in magnitude across ethnicity (except for
African–Americans, for whom no never smoking lung cancer
cases were observed with the risk genotype), suggesting that
tobacco smoking and the recessive IL10 rs1800871 genotype
may interact on a less than multiplicative scale.
Because TNF rs1799964, which appeared to be an impor-
tant SNP for nonsmokers in pooled analysis, does not appre-
ciably vary across ethnic groups, it seems unlikely that popu-
lation stratification was a significant problem. We attempted
to minimize information bias by using strict inclusion and
exclusion criteria for cases and controls, and by implement-
ing stringent quality control measures in our laboratory. We
also used trained interviewers who used standardized ques-
tionnaires to collect detailed information on potential risk
factors and related covariates to address confounding. Differ-
ential recollection of exposures for cases and controls could
result in misclassification bias. Although we included pack-
years of tobacco smoking in regression models to address re-
sidual confounding among ever smokers, our estimates may
still be confounded by the strong effect of smoking. While
we selected SNPs based on a pathway-based approach, addi-
tional markers per gene selected over a range of important
regions (e.g., splice sites, promoter areas, and tagging SNPs)
would have been helpful to better characterize a gene, evalu-
ate haplotypes, and ascertain whether an observed association
could be mediated through linkage with SNPs.
The inverse association estimated for the TNF rs1799964
C variant among never smokers (Table 2) may reflect a true
gene-environment interaction (in which the TNF rs1799964
CC genotype may afford some protection only in the absence
of tobacco smoking) but a number of problems need to be
considered. Data were sparse for some strata across ethnicity,
even among the 920 cases and 825 controls who were self-
identified as White. In particular, there were few observations
of never smokers with the TNF rs1799964 CC variant geno-
type (especially true among cases), and none of the confi-
dence intervals for these strata excluded the null when there
were less than 5 observations per cell. The >60-fold ratios of
the upper and lower 95% confidence limits illustrate the
instability of some of these genotype-smoking estimates.
Cancer is a multifactorial process and a simple determin-
istic SNP-cancer association is unlikely. Given the number of
comparisons that we made, our results could have been
entirely due to chance. Therefore, we used 2 Bayesian
approaches to account for Type I error, which suggest that
our results are not purely chance findings. An inherent fea-
ture of Bayesian correction, though, is the use of subjective
prior probabilities, which is susceptible to publication bias.61
Alternatively, our results may be due to other genetic and/or
epigenetic mechanisms (e.g., gene amplification, translocation,
loss of heterozygosity, DNA methylation, genomic imprint-
ing, and histone modification).62,63 These reasons underscore
the importance of considering our results in the broader con-
text of existing knowledge and studies and not to overempha-
size the results of a particular study.
Differential participation of cases and controls and their
willingness to donate samples for DNA analysis may have
created selection bias. Of the 9 smoking-related sites in our
study, esophageal, liver, lung, and stomach cancers have very
low 5-year survival rates, reflected in the high percentage of
cases in our study who died before they could be interviewed.
Selection bias may exist if factors related to participation
were differentially associated with exposure (e.g., SNP geno-
type) for cases and controls. However, because a potential
participant’s genotype would have been unknown at time of
recruitment, this type of bias seems unlikely. Selection bias
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with survival. However, it is unknown if the study was biased
by this type of selection because a literature search did not
yield sufficient information on the prognostic value of the
SNPs. However, tumor grade and stage did not appear to
vary by SNP genotype (Supporting Information Table S7).
The relatively small number of cases and controls in the
Taixing and MSKCC studies resulted in low statistical preci-
sion, and it had less than 80% power to detect main effect
odds ratios of 1.5 or 0.67 for many of the SNP-cancer associ-
ations. Of the 4 SNPs in the Taixing study with sufficiently
high minor allele frequencies to have at least 80% power
(IL10 rs1800871, IL10 rs1800872, LTA rs909253, and IL6
rs1800796), the 95% confidence intervals from the multivari-
ate model included both positive and inverse associations.
One SNP in the MSKCC study with sufficiently high minor
allele frequency (IL1B rs1143627) was associated with bladder
cancer (aOR ¼ 4.3), but with an extremely wide confidence
interval (95% CI: 1.3–14) (the association did not pass multi-
ple comparisons correction) and was, therefore, not reported.
The LA study had better precision due to its relatively large
sample size for assessing main and smoking-stratified effects
for the lung and UADT sites. The ethnic diversity in the
pooled sample and the LA study also allowed us to examine
ethnicity-specific SNP-cancer associations to assess admix-
ture. Additional strengths include the ability to examine
SNP-cancer associations across a number of different cancer
sites; the use of a population-based study design for the LA
and Taxing studies; and control for multiple comparisons
using 2 Bayesian approaches.
Our results if valid suggest that TNF rs1799964 is inver-
sely associated with smoking-related cancers among never
smokers, and that IL10 rs1800871 is a susceptibility marker
for lung cancer among never smokers, and for oropharyngeal
cancer among ever smokers.
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